Douglas Jones
About Douglas Jones
Douglas Jones is the Director of Cell Therapy Preclinical at Bristol Myers Squibb, with extensive experience in leading discovery and preclinical development teams in the field of cell therapy and immuno-oncology.
Company
Douglas Jones is currently employed at Bristol Myers Squibb as the Director of Cell Therapy Preclinical. Within this role, he works at the Immuno-Oncology and Cell Therapy Thematic Research Center, focusing on delivering engineered cell therapies for cancer patients. His work contributes significantly to developing innovative treatments aimed at improving patient outcomes.
Title
Douglas Jones holds the position of Director, Cell Therapy Preclinical at Bristol Myers Squibb. His leadership extends to overseeing the preclinical development of cell therapy programs. This includes responsibility for the conceptualization, research, and preparation of regulatory documents to ensure compliance and efficacy of therapeutic projects.
Previous Work Experience
Before his current role, Douglas Jones accumulated extensive experience at Repertoire Immune Medicines. He served as a Director from 2019 to 2021 and as Associate Director in 2018. Prior to that, he was a Principal Scientist in 2017 and a Senior Scientist from 2015 to 2017. Earlier in his career, he worked as a Senior Research Scientist at Harvard Medical School from 2014 to 2015 in the Laboratory of Systems Pharmacology.
Education and Expertise
Douglas Jones has an impressive academic background, earning his Doctor of Philosophy (Ph.D.) and Master of Science (M.S.) in Biological Engineering from Stanford University. He was also a Postdoctoral Fellow in the Departments of Systems Biology and Biological Engineering at Harvard University and the Massachusetts Institute of Technology. Additionally, he holds a Bachelor of Science (B.S.) in Chemical Engineering from the University of California, Santa Barbara.
Leadership and Team Management
Throughout his career, Douglas Jones has led multidisciplinary teams through the entire development pipeline, from concept creation to regulatory document preparation. His expertise spans across discovery and preclinical development, demonstrating his capacity to drive forward programs with high potential impact for patient care.